Destiny Pharma is an innovative pharmaceutical company focused on the development of novel medicines that represent a totally different approach to infectious disease.

These novel medicines are being developed to address the growing and unmet demand for prophylaxis and treatment of life-threatening drug-resistant bacteria, often referred to as "superbugs".

Destiny Pharma's XF Drug Platform is being developed to address existing and emerging multi-drug resistant microbial pathogens which cause infections within and outside of hospitals. The lead drug XF-73 is targeted at the prevention of post-surgical Staphylococcal infections. Staphylococcus aureus is the worlds No.1 cause of hospital, bacterial infections. While methicillin-resistant Staphylococcus aureus (MRSA) is the most important and dangerous multi-drug resistant form of the bacteria, recent clinical trials have confirmed that methiciliin-sensitive Staphylococcus aureus (MSSA), the most common form of the bacteria, causes significant infection burden and that there is benefit in addressing all forms of Staphylococcus aureus carriage, i.e. MRSA and MSSA.

Traditional research has failed to fully address these problems. Destiny is pursuing revolutionary approaches to the prevention and treatment of this public health crisis.